

WY-DUR  
Wyoming Drug Utilization Review Board  
Dept. 3375  
1000 E. University Avenue  
Laramie, WY 82071  
307-766-6750

*Aimee Lewis, Pharm.D.*  
*DUR Manager*  
*Kurt Hopfensperger, M.D., J.D.*  
*Chair*  
*Rebecca Ormas, R.Ph.*  
*Vice Chair*

October 1, 2009

Dear Prescriber:

The Wyoming Drug Utilization Review Board is charged with development of prior authorization criteria to address the utilization of medications in the Wyoming Medicaid program. Recently, the Board began reviewing new drugs and formulations as they enter the market. As a part of this process, the Board is asking you to participate in an effort to enlist the expertise of practitioners affected by the following criteria recently drafted by the Board.

New Drug/formulation criteria  
WY-DUR  
September 24, 2009

**Saphris and Fanapt criteria**

Saphris and Fanapt require prior authorization.

A trial of all atypicals (except clozapine) will be required at max dose for 30 days for approval either drug. Adverse events will constitute an end to any trial.

**Onsolis criteria**

Use of Onsolis will require trial and failure of fentanyl transmucosal (Actiq) and fentanyl buccal tablet (Fentora). In addition, Onsolis will be limited to the indication of breakthrough cancer pain in those over the age of 16.

Please provide comments on the listed criteria by October 30, 2009 to my attention at the University of Wyoming School of Pharmacy address provided above. Your participation and guidance to the WY-DUR Board are invaluable and I would like to thank you for taking the time to review the information.

Sincerely,

*Aimee Lewis*

Aimee Lewis, Pharm.D.  
WY-DUR Program Manager